Analysts Anticipate Heska Corp (NASDAQ:HSKA) Will Post Earnings of $0.03 Per Share

Share on StockTwits

Wall Street brokerages predict that Heska Corp (NASDAQ:HSKA) will report $0.03 earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Heska’s earnings, with the highest EPS estimate coming in at $0.10 and the lowest estimate coming in at ($0.05). Heska posted earnings per share of $0.46 in the same quarter last year, which suggests a negative year over year growth rate of 93.5%. The firm is scheduled to report its next earnings results on Tuesday, February 25th.

On average, analysts expect that Heska will report full year earnings of $0.05 per share for the current fiscal year, with EPS estimates ranging from ($0.02) to $0.12. For the next year, analysts anticipate that the firm will post earnings of $0.19 per share, with EPS estimates ranging from $0.03 to $0.34. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Heska.

Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.04) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.04). Heska had a return on equity of 3.17% and a net margin of 3.15%. The firm had revenue of $31.24 million during the quarter, compared to analyst estimates of $30.44 million.

A number of equities research analysts have commented on HSKA shares. Canaccord Genuity restated a “buy” rating and set a $105.00 price objective (up from $75.00) on shares of Heska in a research report on Wednesday, November 6th. Raymond James lowered Heska from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. They noted that the move was a valuation call. Piper Jaffray Companies started coverage on Heska in a research report on Wednesday, September 18th. They set a “neutral” rating and a $68.00 price objective for the company. BidaskClub upgraded Heska from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 27th. Finally, Zacks Investment Research lowered Heska from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $85.75.

NASDAQ HSKA traded down $0.61 during trading on Monday, reaching $94.89. 72,840 shares of the company’s stock were exchanged, compared to its average volume of 89,056. Heska has a fifty-two week low of $62.47 and a fifty-two week high of $104.99. The firm has a market capitalization of $753.36 million, a PE ratio of 66.82 and a beta of 1.08. The company has a current ratio of 8.52, a quick ratio of 6.80 and a debt-to-equity ratio of 0.31. The company’s fifty day simple moving average is $85.48 and its 200-day simple moving average is $78.07.

Several institutional investors have recently made changes to their positions in HSKA. Financial Gravity Wealth Inc. acquired a new stake in shares of Heska during the 2nd quarter valued at about $29,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Heska by 175.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 670 shares of the medical research company’s stock valued at $47,000 after buying an additional 427 shares during the last quarter. Aperio Group LLC acquired a new stake in shares of Heska during the 2nd quarter valued at about $79,000. Quantamental Technologies LLC acquired a new stake in shares of Heska during the 2nd quarter valued at about $120,000. Finally, Bank of Montreal Can lifted its holdings in shares of Heska by 30.3% during the 2nd quarter. Bank of Montreal Can now owns 2,162 shares of the medical research company’s stock valued at $183,000 after buying an additional 503 shares during the last quarter. Institutional investors and hedge funds own 97.92% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Further Reading: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.